Linked Life Data

20726326

Source:http://linkedlifedata.com/resource/pubmed/id/20726326

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-8-23
pubmed:abstractText
The binding of advanced glycation end-products (AGEs) to their receptor (RAGE) may play an important role in the development of diabetic vascular complications. Circulating soluble RAGE (sRAGE) reflects tissue RAGE expression. We examined circulating sRAGE and RAGE -374 T/A gene promoter polymorphism in type 1 diabetic patients and explored their possible associations with the development of nephropathy. Fifty diabetic patients with disease duration >10 years and 20 age, sex and body mass index (BMI) matched healthy controls were included in the study. Diabetic patients were subdivided into 23 patients without nephropathy and 27 with nephropathy. All the studied individuals were subjected to the following investigations: fasting glucose, HbA1c, serum creatinine, lipid profile, albuminuria and sRAGE levels. The -374 T/A RAGE gene polymorphism was studied by PCR amplification and restriction fragment length polymorphism (RFLP) analysis. Our study reported significant increase in sRAGE in diabetic patients compared to controls and in diabetic patients with nephropathy compared to those without nephropathy (P < 0.001). sRAGE was significantly correlated with HbA1c, creatinine, albuminuria and atherogenic lipid profile. There were significant increase in the frequency of RAGE -374 A allele (T/A and/or A/A genotypes) in diabetic patients with nephropathy compared to those without nephropathy and control groups (P < 0.01). A allele was a risk factor for diabetic nephropathy (OR 2.36 & 95% CI 1.1-5.6). RAGE -374 A allele was associated with increased sRAGE levels, hypertension and increased creatinine concentration in diabetic patients. This study points to the possible role of sRAGE as a marker of early nephropathy in diabetic patients. Early testing for the RAGE gene -374 T/A could have merit in predicting risk of diabetic nephropathy later in life.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1110-4902
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
95-106
pubmed:meshHeading
pubmed-meshheading:20726326-Adult, pubmed-meshheading:20726326-Albuminuria, pubmed-meshheading:20726326-Alleles, pubmed-meshheading:20726326-Blood Glucose, pubmed-meshheading:20726326-Creatinine, pubmed-meshheading:20726326-Diabetes Mellitus, Type 1, pubmed-meshheading:20726326-Diabetic Nephropathies, pubmed-meshheading:20726326-Fasting, pubmed-meshheading:20726326-Female, pubmed-meshheading:20726326-Genetic Markers, pubmed-meshheading:20726326-Hemoglobin A, Glycosylated, pubmed-meshheading:20726326-Humans, pubmed-meshheading:20726326-Lipids, pubmed-meshheading:20726326-Male, pubmed-meshheading:20726326-Middle Aged, pubmed-meshheading:20726326-Polymorphism, Restriction Fragment Length, pubmed-meshheading:20726326-Promoter Regions, Genetic, pubmed-meshheading:20726326-Receptors, Immunologic, pubmed-meshheading:20726326-Risk Factors
pubmed:year
2009
pubmed:articleTitle
Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
pubmed:affiliation
Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
pubmed:publicationType
Journal Article